Casper de Clercq

Casper de Clercq is a 25 year veteran of the medical device and life sciences industry. He brings extensive operating experience to NVP having led marketing and commercialization efforts for cardiovascular device， specialty pharmaceutical and diagnostic companies. Based in NVP's Palo Alto office， Casper focuses on mid to late stage investments in medical devices， specialty pharmaceuticals and healthcare services. Therapeutic products that address a critical unmet medical need， that are “less” traumatic or have a defined path to regulatory approval are of particular interest. His current board seats include Basis and Simpirica Spine.

Prior to NVP， Casper was a Partner at U.S. Venture Partners （USVP） in Menlo Park， where he invested in therapeutic companies from clinical development through commercialization. At USVP， Casper served as a Board member for AtheroMed， Ilypsa （acquired by Amgen） and Valeritas. Over a six year period he was actively involved in making and managing investments in more than a dozen companies as a member of the healthcare team. Casper was also a private investor and board member with Innospine， an orthopedic diagnostic company acquired by Kyphon in 2005.